The correlation between clinical presentations and baseline serum inflammatory cytokines before TFESI. by Pornpan Chalermkitpanit (22110121)

Subjects:

Total number of applications to each discipline grouped by (a) clinical disciplines, (b) diagnostic disciplines, and (c) surgical disciplines. by Lucy Hui (17538542)

Number of applicants matched to each discipline grouped by (a) clinical disciplines, (b) diagnostic disciplines, and (c) surgical disciplines. by Lucy Hui (17538542)

Regression analysis of the relationship between intervention and anxiety, depression, sleep quality, quality of life, and clinical pregnancy rate. by Nan Tang (642590)

EF-24 treatment significantly reduces cell viability in leukemia cell lines. by Ajeet P. Singh (22298432)

Subjects:

Mean Values and Standard Deviations (Mean [±SD]) of Clinical Parameters: periodontal probing depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), and plaque ind... by Iva Milinkovic (22331710)

Subjects:

Demographic and clinical data at baseline. by Karel Joineau (21799908)

Subjects:

Clinical characteristics. by Huimin Xian (20390006)

“…</p><p>Conclusions</p><p>In patients with MVD-STEMI, the incidence of MACEs was lower in FCR than in FIR, and the decrease was particularly significant in the DM cohort. …”

Clinical characteristics of reports with finasteride as the primary suspected drug from the FAERS database. by Xiaoling Zhong (181270)

Subjects:

Clinical diagnosis and abnormal signals of AEFIs(/10,000). by Chao Zhang (51048)

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

The top 20 candidate drugs demonstrating the most significant sensitivity differences between high- and low-GSRS subjects. by Yu Zhang (12946)

Subjects:

Clinical prognosis analysis of other DE-ERSRGs except PDHB. by Wan-Jing Zhen (20427813)

Subjects: